The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Editor

Share

Personal info

View

Links

Table of contents

About

Terms

 

Eric J. Topol

Department of Cardiology

Cleveland Clinic Foundation

OH 44195

USA

[email]@ccf.org

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • Department of Cardiology, Cleveland Clinic Foundation, OH 44195, USA. 1999 - 2006
  • Office of the Provost, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, and Cleveland Clinic Foundation, USA. 2005
  • Division of Cardiology, University Hospital, Zurich, Switzerland. 2004
  • Department of Cardiology, Jacobs Center for Thrombosis and Vascular Biology, Cleveland Clinic Foundation, 9500 Euclid Avenue, USA. 1999 - 2003
  • Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA. 2000 - 2002

References

  1. Primary percutaneous coronary intervention vs. fibrinolytic therapy for acute ST-elevation myocardial infarction in the elderly. Karha, J., Topol, E.J. Am. J. Geriatr. Cardiol (2006) [Pubmed]
  2. Physicians and the investment industry. Topol, E.J., Blumenthal, D. JAMA (2005) [Pubmed]
  3. A contemporary assessment of low-molecular-weight heparin for the treatment of acute coronary syndromes: factoring in new trials and meta-analysis data. Topol, E.J. Am. Heart J. (2005) [Pubmed]
  4. Simon Dack Lecture. The genomic basis of myocardial infarction. Topol, E.J. J. Am. Coll. Cardiol. (2005) [Pubmed]
  5. Percutaneous coronary intervention in diabetic patients with non-ST-segment elevation acute coronary syndromes. Roffi, M., Topol, E.J. Eur. Heart J. (2004) [Pubmed]
  6. A coxib a day won't keep the doctor away. Topol, E.J., Falk, G.W. Lancet (2004) [Pubmed]
  7. A guide to therapeutic decision-making in patients with non-ST-segment elevation acute coronary syndromes. Topol, E.J. J. Am. Coll. Cardiol. (2003) [Pubmed]
  8. Cox-2: where are we in 2003? - Cardiovascular risk and Cox-2 inhibitors. Mukherjee, D., Topol, E.J. Arthritis Res. Ther. (2003) [Pubmed]
  9. Randomized, double-blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease. Topol, E.J., Easton, D., Harrington, R.A., Amarenco, P., Califf, R.M., Graffagnino, C., Davis, S., Diener, H.C., Ferguson, J., Fitzgerald, D., Granett, J., Shuaib, A., Koudstaal, P.J., Theroux, P., Van de Werf, F., Sigmon, K., Pieper, K., Vallee, M., Willerson, J.T. Circulation (2003) [Pubmed]
  10. Current status and future prospects for acute myocardial infarction therapy. Topol, E.J. Circulation (2003) [Pubmed]
  11. The rudimentary phase of personalised medicine: coronary risk scores. Topol, E.J., Lauer, M.S. Lancet (2003) [Pubmed]
  12. Need to test the arterial inflammation hypothesis. Bhatt, D.L., Topol, E.J. Circulation (2002) [Pubmed]
  13. Multi-year follow-up of abciximab therapy in three randomized, placebo-controlled trials of percutaneous coronary revascularization. Topol, E.J., Lincoff, A.M., Kereiakes, D.J., Kleiman, N.S., Cohen, E.A., Ferguson, J.J., Tcheng, J.E., Sapp, S., Califf, R.M. Am. J. Med. (2002) [Pubmed]
  14. Economics and quality of care for patients with acute coronary syndromes: the impending crisis. Topol, E.J. Clin. Cardiol (2002) [Pubmed]
  15. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. Topol, E.J., Moliterno, D.J., Herrmann, H.C., Powers, E.R., Grines, C.L., Cohen, D.J., Cohen, E.A., Bertrand, M., Neumann, F.J., Stone, G.W., DiBattiste, P.M., Demopoulos, L. N. Engl. J. Med. (2001) [Pubmed]
  16. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial. Topol, E.J. Lancet (2001) [Pubmed]
  17. Recent advances in anticoagulant therapy for acute coronary syndromes. Topol, E. Am. Heart J. (2001) [Pubmed]
  18. Single nucleotide polymorphisms in multiple novel thrombospondin genes may be associated with familial premature myocardial infarction. Topol, E.J., McCarthy, J., Gabriel, S., Moliterno, D.J., Rogers, W.J., Newby, L.K., Freedman, M., Metivier, J., Cannata, R., O'Donnell, C.J., Kottke-Marchant, K., Murugesan, G., Plow, E.F., Stenina, O., Daley, G.Q. Circulation (2001) [Pubmed]
  19. Debate: PCI or CABG for multivessel disease? Viewpoint: No clear winner in an unfair fight. Bhatt, D.L., Topol, E.J. Curr. Control. Trials. Cardiovasc. Med (2001) [Pubmed]
  20. Acute myocardial infarction: thrombolysis. Topol, E.J. Heart (2000) [Pubmed]
  21. Recognition of the importance of embolization in atherosclerotic vascular disease. Topol, E.J., Yadav, J.S. Circulation (2000) [Pubmed]
  22. Inflammation and embolization in ischemic heart disease. Topol, E.J. J. Invasive. Cardiol (2000) [Pubmed]
  23. Design of the blockade of the glycoprotein IIb/IIIa receptor to avoid vascular occlusion (BRAVO) trial. Topol, E.J., Easton, J.D., Amarenco, P., Califf, R., Harrington, R., Graffagnino, C., Davis, S., Diener, H.C., Ferguson, J., Fitzgerald, D., Shuaib, A., Koudstaal, P.J., Theroux, P., Van de Werf, F., Willerson, J.T., Chan, R., Samuels, R., Ilson, B., Granett, J. Am. Heart J. (2000) [Pubmed]
  24. Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes. Bhatt, D.L., Topol, E.J. JAMA (2000) [Pubmed]
  25. Survival outcomes 1 year after reperfusion therapy with either alteplase or reteplase for acute myocardial infarction: results from the Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO) III Trial. Topol, E.J., Ohman, E.M., Armstrong, P.W., Wilcox, R., Skene, A.M., Aylward, P., Simes, J., Dalby, A., Betriu, A., Bode, C., White, H.D., Hochman, J.S., Emanuelson, H., Vahanian, A., Sapp, S., Stebbins, A., Moliterno, D.J., Califf, R.M. Circulation (2000) [Pubmed]
  26. The role of bivalirudin in percutaneous coronary intervention. Topol, E.J. J. Invasive. Cardiol (2000) [Pubmed]
  27. Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Topol, E.J., Mark, D.B., Lincoff, A.M., Cohen, E., Burton, J., Kleiman, N., Talley, D., Sapp, S., Booth, J., Cabot, C.F., Anderson, K.M., Califf, R.M. Lancet (1999) [Pubmed]
  28. New platelet glycoprotein IIb/IIIa inhibitor trials in percutaneous coronary intervention. Topol, E.J. J. Invasive. Cardiol (1999) [Pubmed]
 
WikiGenes - Universities